A deal with Regeneron announced in April could push the firm's revenue and income totals past $1 billion by year end.

The firm will use the funding to begin a pivotal study of its EGFR inhibitor, advance the Phase I study of its CLK inhibitor, and develop its preclinical pan-KRAS program.

The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...

Researchers at the Broad Institute, Jackson Laboratory, and Boston Children's Hospital will treat rare disease patients and ...

The biotech plans to use the proceeds to develop its pipeline of in vivo CRISPR-based genetic medicines for cardiometabolic disease, including STX-1150.

Biotech Immunome has given the first patient with a solid tumor its fibroblast activation protein (FAP)-targeted radioligand therapy within a clinical trial, the company announced Monday. The ...

If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.

The anti-amyloid drug is designed for a limited course, where patients can stop treatment once they reach a level of ...

Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

The focus on treating people who have no cognitive impairment raises questions about how to implement testing for those at ...

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...

NEW YORK – Eli Lilly has secured full approval for its RET inhibitor Retevmo (selpercatinib) for patients with advanced or metastatic solid tumors that harbor RET fusions, the US Food and Drug ...